Eris Lifesciences gains Brazil regulatory approval for market entry

Eris Lifesciences announced its Ahmedabad manufacturing unit received ANVISA approval, enabling entry into Brazil, South America's largest pharmaceutical market. The approval followed a successful inspection by Brazil's health regulatory agency in May 2025.

Eris is among India's top 20 pharma companies with annual branded formulations revenue exceeding INR 3,000 crore. The company reported FY 25 revenue of INR 2,894 crore, with revenue and operating profit growing 2.6x over five years.